FIELD: medicine, pharmaceutics.
SUBSTANCE: offered is application of eslicarbazepine acetate for preparing a pharmaceutical composition for treating epilepsy including a pharmacologically effective amount of eslicarbazepine acetate where said pharmaceutical composition is to be introduced once a day (as well as a related method of treating epilepsy), as well as application of eslicarbazepine acetate for preparing the pharmaceutical composition containing the pharmacologically effective amount of eslicarbazepine acetate for intensifying the effect of eslicarbazepine on a patient suffering epilepsy where said pharmaceutical composition is to be introduced once a day (as well as the related method of treating).
EFFECT: reduction or control of epileptic attacks in a patient ensured by the application of eslicarbazepine acetate by the declared method, while its efficacy if introduced once a day is higher than if the same total dose is divided onto two intakes (possibly, due to its semi-elimination approximately 20-24 hours) are presented.
50 cl, 2 dwg, 5 tbl
Title | Year | Author | Number |
---|---|---|---|
THERAPEUTIC USE OF ESLICARBAZEPINE | 2008 |
|
RU2488397C2 |
TREATMENT USING ESLICARBAZEPINE ACETATE OR ESLICARBAZEPINE | 2012 |
|
RU2639120C2 |
SOLUBLE DOSAGE FORMS CONTAINING CEPHEM DERIVATIVES APPLICABLE FOR PARENTERAL ADMINISTRATION | 2008 |
|
RU2537237C2 |
PHARMACEUTICAL COMPOSITIONS CONTAINING DGLA, AND USE THEREOF | 2015 |
|
RU2714323C2 |
COMPLEMENT ACTIVITY MODULATORS | 2016 |
|
RU2733720C2 |
COMPLEMENT ACTIVITY MODULATORS | 2016 |
|
RU2769701C2 |
PROLONGED ACTION PHARMACEUTICAL COMPOSITION BASED ON 5-ETHOXY-2-[2-(MORPHOLINO)-ETHYLTHIO]BENZIMIDAZOLE DIHYDROCHLORIDE AND/OR BASE (APHOBAZOLUM) | 2017 |
|
RU2694837C2 |
AMPHETAMINE PRODRUGS WITH MISUSE PROTECTION | 2006 |
|
RU2445085C2 |
PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF HELICOBACTER PYLORI | 2014 |
|
RU2671400C2 |
TACROLIMUS FOR IMPROVED TREATMENT OF PATIENTS WITH GRAFTS | 2009 |
|
RU2574006C2 |
Authors
Dates
2011-04-27—Published
2005-05-06—Filed